Newsfeeds - Spark Newswire

1 minute read

News

Mainz Biomed Taps Labor Staber to Expand ColoAlert Commercialization in Germany

Today, 10:33 AM

Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr

MYNZ

1 minute read

Mainz Biomed Executed Its Option From Uni Targeting Research To Acquire The Previously Licensed Scientific Intellectual Property For Its Flagship Product Coloalert, A Detection Test For Colorectal Cancer

By Benzinga Newsdesk

Today, 10:33 AM

The Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. to outright purchase intellectual property, including a pending patent, associated with a portfolio of novel gene

MYNZ

1 minute read

Mainz Biomed Has Established Commercial Partnerships For Coloalert With Marylebone Laboratory And Instituto De Microecologia, Two Independent Laboratories Covering England And Spain

By Benzinga Newsdesk

Today, 10:33 AM

ColoAlert, Mainz Biomed's flagship product, an easy-to-use, at-home detection test for colorectal cancer (CRC), is currently being commercialized across Europe and in select international markets via a

MYNZ

1 minute read

JonesTrading Initiates Coverage On Mainz Biomed with Buy Rating, Announces Price Target of $11

By Benzinga Newsdesk

Today, 10:33 AM

JonesTrading analyst Justin Walsh initiates coverage on Mainz Biomed (NASDAQ:MYNZ) with a Buy rating and announces Price Target of $11.

MYNZ

2 minute read

FDA
News

Mainz Biomed Earlier Announced IRB Approval and Initiation of US Pivotal FDA Clinical Study; Shares Up 18% Premarket

By Charles Gross

Today, 10:33 AM

Mainz Biomed NV (NASDAQ: MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has received approval from an independent Institutional Review Board (IRB) for the protocol ReconAAsense, the Company's U.S.

MYNZ